NCT06180967View on ClinicalTrials.gov

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

September 3, 2020

Primary Completion Date

October 20, 2020

Study Completion Date

October 20, 2020

Conditions

Healthy

Interventions

DRUG

Midazolam Syrup

Administered Orally.

DRUG

Midazolam Solution

Administered IV bolus.

DRUG

Pirtobrutinib

Administered Orally.

Trial Locations (1)

32117

Covance Clinical Research Unit, Daytona Beach

Sponsors

Collaborators (1)

Loxo Oncology, Inc.

All Listed Sponsors

collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT06180967 - A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants | Biotech Hunter | Biotech Hunter